These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22495586)

  • 21. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
    Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
    Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3).
    Aldrich A; Bosch ME; Fallet R; Odvody J; Burkovetskaya M; Rama Rao KV; Cooper JD; Drack AV; Kielian T
    Ann Neurol; 2016 Dec; 80(6):909-923. PubMed ID: 27804148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of phosphodiesterase IV enzyme improves locomotor and sensory complications of spinal cord injury via altering microglial activity: Introduction of Roflumilast as an alternative therapy.
    Moradi K; Golbakhsh M; Haghighi F; Afshari K; Nikbakhsh R; Khavandi MM; Faghani S; Badripour A; Etemadi A; Ashraf-Ganjouei A; Bagheri S; Dehpour AR
    Int Immunopharmacol; 2020 Sep; 86():106743. PubMed ID: 32619958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.
    Ding H; Li N; He X; Liu B; Dong L; Liu Y
    Int Urol Nephrol; 2017 Oct; 49(10):1723-1730. PubMed ID: 28756610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing.
    Seehase S; Lauenstein HD; Schlumbohm C; Switalla S; Neuhaus V; Förster C; Fieguth HG; Pfennig O; Fuchs E; Kaup FJ; Bleyer M; Hohlfeld JM; Braun A; Sewald K; Knauf S
    PLoS One; 2012; 7(8):e43709. PubMed ID: 22952743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternatives to indicating roflumilast and the chronic obstructive pulmonary disease classification.
    Blasco LM
    Arch Bronconeumol; 2012 Sep; 48(9):343. PubMed ID: 22503591
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beta-adrenergic stimulation contributes to maintenance of endothelial barrier functions under baseline conditions.
    Spindler V; Waschke J
    Microcirculation; 2011 Feb; 18(2):118-27. PubMed ID: 21166930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclic nucleotide second messengers (cAMP and cGMP) play a central role in signal transduction and regulation of mesenteric postcapillary fluid leak.
    Chong TJ; Victorino GP
    J Trauma; 2005 Aug; 59(2):302-6; discussion 306-7. PubMed ID: 16294068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.
    Barone FC; Barton ME; White RF; Legos JJ; Kikkawa H; Shimamura M; Kuratani K; Kinoshita M
    Pharmacology; 2008; 81(1):11-7. PubMed ID: 17726343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs.
    Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D; Mokrý J
    Exp Lung Res; 2017; 43(9-10):407-416. PubMed ID: 29220595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PDE4 Inhibitors Roflumilast and Rolipram Rescue ADO2 Osteoclast Resorption Dysfunction.
    Hong JM; Gerard-O'Riley RL; Acton D; Alam I; Econs MJ; Bruzzaniti A
    Calcif Tissue Int; 2024 Apr; 114(4):430-443. PubMed ID: 38483547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
    Rutter AR; Poffe A; Cavallini P; Davis TG; Schneck J; Negri M; Vicentini E; Montanari D; Arban R; Gray FA; Davies CH; Wren PB
    J Pharmacol Exp Ther; 2014 Jul; 350(1):153-63. PubMed ID: 24784567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphodiesterase 4 inhibition attenuates atrial natriuretic peptide-induced vascular hyperpermeability and loss of plasma volume.
    Lin YC; Samardzic H; Adamson RH; Renkin EM; Clark JF; Reed RK; Curry FR
    J Physiol; 2011 Jan; 589(Pt 2):341-53. PubMed ID: 21098005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.
    Liu X; Hao PD; Yang MF; Sun JY; Mao LL; Fan CD; Zhang ZY; Li DW; Yang XY; Sun BL; Zhang HT
    Psychopharmacology (Berl); 2017 Aug; 234(16):2409-2419. PubMed ID: 28477089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase-4 inhibitors reduce the expression of proinflammatory mediators by human epidermal keratinocytes independent of intracellular cAMP elevation.
    Kataoka S; Takaishi M; Nakajima K; Sano S
    J Dermatol Sci; 2020 Dec; 100(3):230-233. PubMed ID: 33109421
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical Considerations for Roflumilast: A New Treatment for COPD.
    Kelly Freeman ML
    Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The direct thrombin inhibitor melagatran counteracts endotoxin-induced endothelial leukocyte adherence and microvascular leakage in the rat mesentery. Rationale for the treatment of inflammatory disorders beyond sepsis?
    Leithäuser B; Fassbender M; Eickhoff M; Elg M; Eichner G; Matthias FR
    Clin Hemorheol Microcirc; 2007; 36(4):277-89. PubMed ID: 17502698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia.
    Barreiro E; Puig-Vilanova E; Salazar-Degracia A; Pascual-Guardia S; Casadevall C; Gea J
    J Appl Physiol (1985); 2018 Aug; 125(2):287-303. PubMed ID: 29648516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.